Actemra IV (tocilizumab) / Roche, JW Pharma - LARVOL DELTA

GLOBRYTE: A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma (clinicaltrials.gov) - P3 | N=182 | Recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Jun 2027 ➔ Sep 2027

Trial completion date • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology • CCND1

CAR T-Cell Therapy Use in Rare Lymphoid Malignancies: A Single-Center Experience (SOHO 2025) - "He received Axi-Cel, with a course complicated by grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS) and grade 1 cytokine release syndrome (CRS), requiring steroids, tocilizumab, and anakinra...Case 3: A 62-year-old male with isolated CNS relapse of DLBCL received Axi-Cel after failing methotrexate (MTX)-based treatment... This report adds evidence supporting CAR-T therapy in challenging conditions like PTLD and CNSL, where larger clinical trials are ongoing or difficult to conduct."

CAR T-Cell Therapy • Clinical • B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Eye Cancer • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Interleukin-6 Is a Potential Therapeutic Target in Refractory Immunotherapy-Mediated Cholangiopathy (ACG 2025) - "Her medical history is significant for stage IIIa chronic kidney disease and metastatic triple-negative breast cancer treated with bilateral mastectomy and adjuvant chemotherapy with 2 cycles of carboplatin, paclitaxel and pembrolizumab...Pembrolizumab was discontinued, and she was started on prednisone 80mg for presumed ICI hepatitis with adequate response. Despite steroids and mycophenolate mofetil (MMF), her labs again worsened (ALP 1138, AST 158, ALT 397, bilirubin 11.9)...Her bilirubin continued to rise despite treatment with high-dose prednisone, budesonide, ursodiol, and tacrolimus...IL-6 may serve as a biomarker predicting tocilizumab response with borderline elevation potentially being explained by steroid and tacrolimus administration. Further studies are warranted to establish diagnostic criteria and treatment strategies for this challenging irAE.Figure: Trends of Direct Bilirubin Over Time"

IO biomarker • Breast Cancer • Chronic Kidney Disease • Hepatology • Immunology • Infectious Disease • Nephrology • Renal Disease • Solid Tumor • Triple Negative Breast Cancer • IL6

CA061-1001: A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1) (clinicaltrials.gov) - P1 | N=270 | Recruiting | Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | N=144 ➔ 270

Enrollment change • Immunology • Inflammatory Arthritis • Lupus • Myositis • Rheumatoid Arthritis • Rheumatology • Scleroderma • Systemic Lupus Erythematosus • Systemic Sclerosis

Coming to a hard stop? Effect of tapered tocilizumab after weekly tocilizumab cessation for giant cell arteritis: a multicentre evaluation. (PubMed, Rheumatology (Oxford)) - "Tapering TCZ after qwTCZ cessation delayed relapse only during the tapering period, but only in adequate responders to qwTCZ. No lasting benefit was seen after tapering ended."

Journal • Giant Cell Arteritis • Immunology • Infectious Disease • Novel Coronavirus Disease • Vasculitis

Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma. (PubMed, Blood Cancer J) - "Among these, 1276 patients received BCMA BsAbs, 841 treated with GPRC5D/FcRH5 BsAbs, 157 received teclistamab + talquetamab, and 65 patients received a talquetamab + daratumumab, and 35 patients received talquetamab + pomalidomide...CRS and the need for tocilizumab were significantly less frequent with BCMA BsAbs vs GPRC5D/FcRH5 BsAbs, (P < 0.002)...GPRC5D/FcRH5 are associated with less grade 3/4 hematologic toxicity whereas BCMA BsAbs were associated with lower grade 3/4 CRS rates, compared to GPRC5D/FcRH5. These insights are crucial for guiding treatment decisions and developing strategies to improve patient outcomes."

Adverse events • Journal • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Neutropenia • Oncology • Thrombocytopenia

Real-world effectiveness and safety of tocilizumab in the management of polymyalgia rheumatica: a retrospective study from the KEIO-PMR cohort. (PubMed, Rheumatol Int) - "Tocilizumab effectively reduced relapse rates and demonstrated glucocorticoid-sparing effects in patients with refractory PMR in the real world, with no significant safety issues. These results further support the existing evidence that tocilizumab may be a promising treatment option in real-world settings."

Journal • Real-world evidence • Retrospective data • Giant Cell Arteritis • Immunology • Musculoskeletal Pain • Pain • Rheumatology • CRP

Distinct platelet transcriptomic heterogeneity in respiratory illnesses and modulation by corticosteroids and immune antibody treatments. (PubMed, J Transl Med) - "A systematic investigation of platelet transcriptomic heterogeneity in respiratory infections, combined with the delineation of its therapeutic modulation by dexamethasone and tocilizumab, advances the understanding of platelet involvement in immune-thrombotic dysregulation and provides a foundation for exploring potential therapeutic targets."

Heterogeneity • Journal • Immunology • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8

Safety, Efficacy, and Length-of-Stay Analysis of Outpatient CAR-T Therapy in Non-Hodgkin Lymphoma Patients at a Community-Based Medical Center (SOHO 2025) - "Objectives: Assess the safety, tolerability, and outcomes of outpatient CAR-T therapy for non-Hodgkin lymphoma patients treated with axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel), tisagenlecleucel (tisa-cel), or brexucabtagene autoleucel (brexu-cel) in a community setting...None received prophylactic dexamethasone or tocilizumab... Outpatient CAR-T therapy is feasible with comparable safety, efficacy, and improved cost effectiveness based on lower length of hospital stay. Larger prospective studies are warranted."

Clinical • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Nodal Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Targeted Delivery of CD34 Aptamer-Coupled Tocilizumab Microspheres for Effective Treatment of Thyroid-Associated Ophthalmopathy. (PubMed, Invest Ophthalmol Vis Sci) - "In vivo, a TAO mouse model treated with anti-mouse IL-6R microspheres (anti-mmu-IL-6R-MS) and CD34 aptamer-modified anti-mmu-IL-6R microspheres (anti-mmu-IL-6R-MS-CD34 Apt) demonstrated significant reductions in tissue inflammation, fibrosis, and ECM protein levels, with notable inhibition of the STAT3 signaling pathway. These findings highlight the potential of CD34 aptamer-coupled Toc microspheres as a targeted therapy for TAO, providing a comprehensive strategy that addresses local manifestations of the disease."

Journal • Endocrine Disorders • Fibrosis • Grave’s Disease • Immunology • Inflammation • Ophthalmology • Thyroid Eye Disease • CD34 • IL6R • TGFB1

Efficacy and safety of tocilizumab in covid-19 critically ill patients: a multicenter cohort study (ERS 2025) - No abstract available

Clinical • Infectious Disease • Novel Coronavirus Disease

The Therapeutic Effects of Semaglutide in Congenital Linear Scleroderma. (PubMed, Cureus) - "Various treatments have been proposed, including D-penicillamine, phototherapy, oral vitamin D, and immunosuppressants such as methotrexate (MTX), cyclosporine, and interleukin-6 (IL-6) inhibitors. We present the case of a 14-year-old female patient with refractory CLS, whose condition continued to worsen despite treatment with tocilizumab, mycophenolate mofetil (MMF), and MTX. She was subsequently started on a glucagon-like peptide-1 (GLP-1) receptor agonist and began to experience improved mobility in her left arm and decreased skin hardening. To our knowledge, this is the first reported case suggesting the potential role of GLP-1 receptor agonists in slowing the progression of localized scleroderma, possibly due to their anti-fibrotic and anti-inflammatory effects."

Journal • Immunology • Rheumatology • Scleroderma • Systemic Sclerosis • IL6

Dabrafenib/Trametinib-Induced Immune-Related Cholangiopathy Managed With Systemic Corticosteroids and Tocilizumab (ACG 2025) - "Though not commonly associated with severe cholangiopathy, dabrafenib/trametinib therapy may induce immune-mediated bile duct injury or direct hepatocellular toxicity in susceptible individuals. Early recognition of this rare complication of targeted therapy and distinction from infectious, obstructive, or other drug-induced etiologies is important for management and prognosis, with systemic corticosteroids and tocilizumab available as effective treatment options."

Gastroenterology • Hepatology • Liver Failure • Melanoma • Solid Tumor

Advances in mechanistic investigation and treatment of steroid-refractory ICI-induced liver injury. (PubMed, Clin Exp Med) - "Recent advancements in therapeutic research have identified promising second-line treatments, including immunosuppressants (tacrolimus, cyclosporine A, mycophenolate mofetil, and azathioprine), monoclonal antibodies (infliximab and tocilizumab), anti-thymocyte globulin, intravenous immunoglobulin, ursodeoxycholic acid for cholestatic cases, and blood purification techniques. Furthermore, we discuss the development of novel therapies informed by evolving insights into the condition's pathogenesis and the feasibility of reintroducing ICIs after ICI-DILI resolution. These advancements mark significant progress in optimizing patient outcomes and advancing the mechanistic understanding of ICI-DILI."

IO biomarker • Journal • Review • Hepatology • Liver Failure • Oncology • ABCB1 • PD-L1 • PD-L2

Single-Center Cross-Sectional Analysis of Patients with RA, SpA, and PsA: Data from the Prescription Database. (PubMed, J Pers Med) - "For RA, 34.2% of patients were difficult to treat (D2T) (98 pt), 54.8% (157 pt) were in monotherapy (tocilizumab-sarilumab-upadacitinib-filgotinib). Abatacept was the most prescribed treatment in RF and ACPA-positive patients and in those with ILD. The anti-IL-17A secukinumab was prescribed in 12% of SpA, of which 71% had enthesitis and dactylitis (14 pt). Ixekizumab was prescribed in 10.4% of PsA patients over 65 years with previous CV events, enthesitis, and dactylitis (21 pt). Apremilast was present in 71% of PsA with previous cancer...The cross-sectional analysis of prescriptions in patients with RA, SpA, and PsA demonstrates how the ITABIO recommendations can guide towards the correct appropriateness of prescription. RA and especially D2T-RA remains the disease with the greatest therapeutic failures, with the highest percentage of monotherapy (anti-IL-6 and Jak-i) and of discontinuation of MTX."

Journal • Ankylosing Spondylitis • Cardiovascular • Diabetes • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Infectious Disease • Inflammatory Arthritis • Inflammatory Bowel Disease • Interstitial Lung Disease • Metabolic Disorders • Ocular Inflammation • Oncology • Ophthalmology • Psoriatic Arthritis • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • Uveitis • IL17A

Tocilizumab for the Management and Prevention of Cytokine Release Syndrome in Hematologic Malignancies: A Systematic Review of Clinical Evidence (SOHO 2025) - "Tocilizumab is effective for CRS treatment and prevention in hematologic malignancies. While generally safe, early use may cause neurotoxicity or infection in selected patients. Further prospective trials are needed to optimize timing and patient selection."

Clinical • Cytokine release syndrome • Review • Hematological Malignancies • Oncology • IL6

A Case of Large Vessel Giant Cell Arteritis Presenting With Abdominal Pain, Constipation, and Unintentional Weight Loss (ACG 2025) - "Patient was discharged with daily bowel regimen, oral steroids, and plan to start tocilizumab as outpatient per rheumatology and vascular surgery teams...A broad differential inclusive of vasculitis should be considered when patients develop new abdominal pain and colonic dysmotility. This case also demonstrates the importance of thorough history taking, review of systems (such as headache and jaw claudication in our patient) and contrast imaging in the evaluation and diagnostic workup of new GI complaints to avoid missing potential systemic disease processes such as vasculitis.Figure: Image A: CT angiogram detailing irregular multifocal enhancement of the abdominal aorta with superior mesenteric artery involvement; Images B & C: mild inflammation and shallow ulcerations from the descending colon to the ano-rectal verge."

Clinical • Cardiovascular • Constipation • Diabetes • Gastroenterology • Gastrointestinal Disorder • Giant Cell Arteritis • Hypertension • Immunology • Inflammation • Metabolic Disorders • Pain • Rheumatology • Type 2 Diabetes Mellitus • Vasculitis

Efficacy and Safety of Tocilizumab Combined with Immunoglobulin in steroid-refractory/ resistant pneumonitis related to immune checkpoint blockade: A Retrospective Study (ESMO 2025) - No abstract available

Checkpoint block • Checkpoint inhibition • Retrospective data • Oncology

Cytokine release syndrome in solid tumors. (PubMed, Cancer) - "Management of CRS involves supportive care for mild cases, whereas severe presentations often require targeted therapies like tocilizumab, corticosteroids, and escalation to the intensive care unit for organ support...Future research focuses on refining risk stratification tools, novel therapeutic agents, and evaluating long-term outcomes. A deeper understanding of CRS in solid tumors will enable more personalized treatment approaches, enhancing the safety and efficacy of immunotherapies for this patient population."

Journal • Review • Critical care • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor

CARing for ALL: A Multicenter Real-World Study of ALL Patients Treated with CAR T-cell Therapy Using the TriNetX Database (SOHO 2025) - "Tisagenlecleucel and brexucabtagene autoleucel are both anti-CD19 CAR T-cell therapies...In the adult group, 45% of patients required tocilizumab for complications, 39.2% patients received it in the pediatric group... ALL patients being administered CAR T-cell therapy experience a significant number of adverse effects, 2 of 5 patients develop CRS; almost 1 of 5 adult patients develop ICANS. Mortality among the adult and pediatric groups was noted to be similar at 30%; historically, outcomes for adult ALL patients have been worse as compared to their pediatric counterparts. Adult patients have a higher prevalence of comorbidities."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

Best of Cell Therapy for Lymphoma: What We Learned in 2024 and 2025 (SOHO 2025) - P1/2, P2 | "Autologous CAR-T Therapy CD19 CAR-T New Regulatory Approvals In March 2024, the United States Food and Drug Administration (FDA) granted accelerated approval to lisocabtagene maraleucel (lisocel) for relapsed/refractory (R/R) chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL) after Bruton tyrosine kinase inhibitors (BTKis) and B-cell lymphoma 2 (BCL2) inhibitors, making it the first CAR-T approval in this disease...Long-Term Follow-up of Pivotal CD19 CAR-T Trials TRIAL (PRODUCT) LYMPHOMA SUBTYPE MEDIAN FU (MONTHS) ORR (%) CR (%) MEDIAN PFS (MONTHS) PFS (%) OS (%) NOTABLE SAFETY FINDINGS 64.6 90 75 (79% in FL cohort, 65% in MZL cohort) 62.2 53 (5 yr) 69 (5 yr) No new late signals ZUMA-5 (AXICEL) FL/MZL ( ≥ 3L) ELARA (TISA-CEL) FL ( ≥ 3L) 53 – * 69.1 53.3 50.2 (4 yr) 79.3 (4 yr) No new late signals; 6.2% secondary primary malignancies TRANSCEND FL (LISO-CEL) FL (2L+ high-risk/3L+) 29.5 – 30 95.7 – 97.1 94.2 – 95.7 NR 72.5 – 82.6 (2 yr) 88.2 –..."

IO biomarker • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hodgkin Lymphoma • Indolent Lymphoma • Large B Cell Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Oncology • Peripheral T-cell Lymphoma • Small Lymphocytic Lymphoma • T Cell Non-Hodgkin Lymphoma • CD22 • CD5 • IL15 • TNFRSF8

Tocilizumab for Steroid Pulse-Refractory Cytokine Release Syndrome in Chemotherapy With Durvalumab Plus Tremelimumab for NSCLC: A Case Report. (PubMed, JTO Clin Res Rep) - "Therefore, reports of CRS were rare in NSCLC, but after approval of anti-programmed cell death protein-1 and anti-programmed death-ligand 1 plus anti-CTLA-4 antibodies, reports of CRS are increasing. We, here, report two cases of successful tocilizumab treatment for steroid pulse-refractory CRS in chemotherapy with durvalumab plus tremelimumab for NSCLC."

Journal • Inflammation • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Rare Case of Giant Cell Arteritis Presenting With Progressive Dysphagia and Lingual Infarction (ACG 2025) - "Temporal artery biopsy revealed bilateral transmural inflammation, consistent with GCA, though giant cells were not seen.Treatment included prednisone 60 mg daily and aspirin 81 mg daily. First-line therapy includes high-dose steroids and aspirin, but refractory cases may require advanced treatments like tocilizumab.GCA should be considered in elderly patients presenting with dysphagia and systemic symptoms, even in the absence of classic features. Prompt recognition and treatment are essential, making rare presentations valuable in improving patient care."

Clinical • Cardiovascular • Gastrointestinal Disorder • Giant Cell Arteritis • Immunology • Inflammation • Otorhinolaryngology • Vasculitis

Management of Rheumatoid Arthritis in a Patient with Aplastic Anemia and Ulcerative Colitis: A Case Report. (PubMed, Am J Case Rep) - "Hydroxychloroquine was initially selected over methotrexate due to its relatively lower risk of bone marrow suppression, an important consideration in patients with underlying aplastic anemia...Sarilumab was introduced but led to recurrent anemia and thrombocytopenia...Tocilizumab proved to be an effective and well-tolerated treatment option, demonstrating the importance of individualized therapy and close hematologic monitoring. Further research is needed to optimize treatment strategies for RA in patients with concurrent aplastic anemia."

Journal • Anemia • Aplastic Anemia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Rheumatoid Arthritis • Rheumatology • Thrombocytopenia • Ulcerative Colitis

Tocilizumab for Lung Cancer-Associated Cachexia: A Multicenter, Single-Arm, Phase II Pilot Study (ESMO 2025) - No abstract available

Clinical • P2 data • Lung Cancer • Oncology • Solid Tumor